Breaking News

Aduro Biotech Receives Milestone Payment From Janssen

Submission of investigational new drug application for ADU-214 in lung cancer

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Aduro Biotech Inc. has received a milestone payment from Janssen Biotech Inc. for Aduro’s submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration for ADU-214, a LADD immunotherapy in development for the treatment of non-small cell lung cancer. The IND will enable Janssen, Aduro’s license partner for ADU-214, to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-214. “We are pleased t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters